Journal article
Sofosbuvir and daclatasvir therapy in patients with hepatitis C-related advanced decompensated liver disease (MELD ≥ 15)
GW McCaughan, PA Thwaites, SK Roberts, SI Strasser, J Mitchell, B Morales, S Mason, P Gow, A Wigg, C Tallis, G Jeffrey, J George, AJ Thompson, FC Parker, PW Angus
Alimentary Pharmacology and Therapeutics | WILEY | Published : 2018
DOI: 10.1111/apt.14404
Abstract
Background: Antiviral therapy for hepatitis C has the potential to improve liver function in patients with decompensated cirrhosis. Aims: To examine the virological response and effect of viral clearance in patients with decompensated hepatitis C cirrhosis all with MELD scores ≥15 following sofosbuvir/daclatasvir ± ribavirin. Methods: We prospectively collected data on patients who commenced sofosbuvir/daclatasvir for 24-weeks under the Australian patient supply program (TOSCAR) and analysed outcomes including sustained viral response at 12 weeks (SVR12), death and transplant. Results: 108 patients (M/F, 79/29; median age 56years; Child-Pugh 10; MELD 16; genotype 1/3, 55/47) received sofosbu..
View full abstractGrants
Funding Acknowledgements
Funds received from Gilead Sciences and Bristol-Myers Squibb.